Description

Therapeutic proteins are fast-acting and potent medicines and have proved very successful in the treatment of a wide range of indications. Therapeutic proteins are extensively used in the treatment of cancer, HIV, and other diseases. The global therapeutic protein market is set to grow by US$ 138 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for therapeutic protein. The global therapeutic protein market is segmented on the basis of product, process, region. By product, it is categorized into monoclonal antibodies, vaccines, peptide hormones, coagulation factors, cytokines, therapeutic enzymes, and peptide antibiotics. The monoclonal antibodies segment held the largest market share in 2020. By process, the therapeutic protein market is divided into cell culture, microbial fermentation, natural source, and others. The cell culture segment accounted for the largest market share in 2020. Based on region, the therapeutic protein market is divided into North America, Asia Pacific, Europe, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, CSL Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Grifols S.A., Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Co. Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the therapeutic protein market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: monoclonal antibodies, vaccines, peptide hormones, coagulation factors, cytokines, therapeutic enzymes, and peptide antibiotics
Process: cell culture, microbial fermentation, natural source, and others
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the global therapeutic protein market
Pinpoint growth sectors and trends for investment
Understand what the future of the global therapeutic protein market looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Therapeutic Protein Market by Product
4.1 Monoclonal Antibodies
4.2 Vaccines
4.3 Peptide Hormones
4.4 Coagulation Factors
4.5 Cytokines
4.6 Therapeutic Enzymes
4.7 Peptide Antibiotics
5. Therapeutic Protein Market by Process
5.1 Cell Culture
5.2 Microbial Fermentation
5.3 Natural Source
5.4 Others
6. Therapeutic Protein Market by Region
6.1 North America
6.2 Asia Pacific
6.3 Europe
6.4 Rest Of The World (Row)
7. Company Profiles
7.1 AbbVie Inc.
7.2 Alexion Pharmaceuticals, Inc.
7.3 Amgen Inc.
7.4 BioMarin Pharmaceutical Inc.
7.5 Bristol-Myers Squibb Company
7.6 CSL Limited
7.7 Eli Lilly and Company
7.8 F. Hoffmann-La Roche AG
7.9 GlaxoSmithKline plc
7.10 Grifols, S.A.
7.11 Johnson & Johnson
7.12 Merck KGaA
7.13 Novartis AG
7.14 Novo Nordisk A/S
7.15 Pfizer Inc
7.16 Sanofi SA
7.17 Takeda Pharmaceutical Co. Ltd.
8. Appendix
8.1 About StrategyHelix
8.2 Disclaimer